Yahoo Malaysia Web Search

Search results

1. www.astrazeneca.comAstraZeneca - Research-Based BioPharmaceutical Company

   www.astrazeneca.com

   • Cached

   AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

   • Careers

     A.Catalyst Network is an interconnected and dynamic global...

   • What science can do

     What science can do - AstraZeneca - Research-Based...

   • R&D

     Any reference in these archives to AstraZeneca products or...

   • Our therapy areas

     CVRM (Cardiovascular, Renal and Metabolism) is one of our...

   • Our company

     At AstraZeneca, sustainability is part of our DNA, embedded...

   • Investors

     Investors - AstraZeneca - Research-Based BioPharmaceutical...

   • Media

     Media - AstraZeneca - Research-Based BioPharmaceutical...

   • Sustainability

     Sustainability - AstraZeneca - Research-Based...

2. en.wikipedia.org › wiki › AstraZenecaAstraZeneca - Wikipedia

   en.wikipedia.org › wiki › AstraZeneca

   • Cached

   AstraZeneca plc (⫽ ˌ æ s t r ə ˈ z ɛ n ə k ə ⫽) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

3. Top stories

   • MarketWatch

     AstraZeneca PLC ADR falls Monday, underperforms market

     AstraZeneca PLC ADR closed $3.73 short of its 52-week high ($80.86), which the company reached on June 6th.

     1 hour ago

   • VN Express on MSN.com

     K Hospital, AstraZeneca promote Vietnamese healthcare research

     6 hours ago

   • scmp.com on MSN.com

     Safety concerns behind Hong Kong abandoning AstraZeneca’s Covid-19 vaccines, new book says

     1 day ago

   • Business Insider

     AstraZeneca: Strong Sales Growth and Upward Guidance Potential Justify Buy Rating

     Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price target at p14,500.00. Sachin Jain has given his Buy rating due to a combination of factors including AstraZeneca’s ...

     18 hours ago

   • MarketWatch

     AstraZeneca outperforms market despite losses on the day

     AstraZeneca PLC AZN shares inched down 0.10% to £120.44 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.13% to 8,193.49. Supported by world-class markets data from Dow Jones and ...

     7 hours ago

   View all

4. www.bbc.co.uk › news › health-68977026AstraZeneca to withdraw Covid vaccine - BBC News

   www.bbc.co.uk › news › health-68977026

   • Cached

   May 8, 2024 · After more than three billion doses, the Oxford-AstraZeneca Covid vaccine is being withdrawn. AstraZeneca said it was "incredibly proud" of the vaccine, but it had made a commercial decision.

5. www.who.int › news-room › feature-storiesThe Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19...

   www.who.int › news-room › feature-stories

   • Cached

   Jun 13, 2022 · The AstraZeneca vaccine is safe and effective at protecting people from the extremely serious risks of COVID-19, including death, hospitalization and severe disease. Read the 16 April 2021 statement of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine for reports of very rare side effects.

6. www.nytimes.com › interactive › 2020How the Oxford-AstraZeneca Vaccine Works (Published 2022)

   www.nytimes.com › interactive › 2020

   The Oxford-AstraZeneca vaccine for Covid-19 is more rugged than the mRNA vaccines from Pfizer and Moderna. DNA is not as fragile as RNA, and the adenovirus’s tough protein coat helps protect...

7. www.who.int › publications › mAstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

   www.who.int › publications › m

   • Cached

   The AstraZeneca ChAdOx1-S/nCoV-19 [recombinant] vaccine resource includes key information on the vaccine specific requirements. UPDATED. Manufacturers: The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19).

8. www.astrazeneca.com › media-centre › press-releasesCOVID-19 Vaccine AstraZeneca confirms 100% protection against...

   www.astrazeneca.com › media-centre › press-releases

   • Cached

   Feb 3, 2021 · The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. Results demonstrated vaccine efficacy of 76% ...